NMPA Holds 2026 Medical Device Regulatory System Research Project Report Meeting in Yantai, Shandong

Key Summary

The National Medical Products Administration (NMPA) convened the 2026 Report Meeting on Medical Device Regulatory System Research Projects in Yantai, Shandong, hearing interim reports from nine lead units—including the Beijing, Shanghai and Shandong provincial/municipal administrations—on 12 research projects covering six areas such as production supervision, supervisory sampling and testing, and adverse event monitoring, and discussing the direction of future regulatory policy.

The meeting stated that research on regulations and regulatory systems is a hard task tied to science-based regulatory decision-making and to the safety of medical devices used by the public, and required all units to align their research with the priorities of regulatory reform and to serve regulatory decision-making with high-quality outputs.

The meeting signals that medical device regulations will continue to be refined and that regulatory research is becoming more granular, spanning product registration, quality management systems and post-market surveillance. It carries significant guidance for device manufacturers' compliance strategies and choice of registration pathways.

Source and Applicability Note

• Source authority: NMPA Medical Devices
• Original publication date: 3 July 2026
• Source link: https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/ylqxhyxx/20260703210757130.html

This article is compiled from public information released by NMPA Medical Devices. Specific requirements remain subject to the latest official publications of the regulatory authority.

Full Translated Text

On 3 July, the 2026 Report Meeting on Medical Device Regulatory System Research Projects was held in Yantai, Shandong. The meeting heard reports from nine lead units responsible for regulatory system research projects—including the Beijing, Shanghai and Shandong provincial (municipal) administrations—on the status of 12 research projects, held panel discussions and exchanges, and discussed the direction of future regulatory policy research.

The meeting fully affirmed the interim research results achieved by the units across six areas, including medical device production supervision, supervisory sampling and testing, and adverse event monitoring. The meeting noted that, in the face of new circumstances and new challenges, research on regulations and regulatory systems is a hard task that bears on science-based regulatory decision-making and on the safety of medical devices used by the public. All units should continue to identify patterns from regulatory practice, closely integrate their research work with the priorities of regulatory reform, conduct in-depth research, systematically summarize findings and keep to timelines, so as to serve regulatory decision-making with high-quality research results.

Relevant departments and directly affiliated units of the NMPA, responsible officials of certain provincial and municipal administrations, and representatives of certain industry associations and universities attended the meeting.

AIMEILI Regulatory Interpretation and Business Impact

On 3 July 2026, the NMPA held the medical device regulatory system research project report meeting in Yantai, presenting interim results from 12 projects across six major areas, including production supervision, supervisory sampling and testing, and adverse event monitoring. As a consultancy specializing in international medical device registration, AIMEILI reads this meeting as a signal that regulatory research is being deepened and that regulatory decision-making is becoming more science-based. The implications for Chinese medical device companies, including exporters, are multi-dimensional:

1. Registration pathways and product classification

The research projects cover production supervision and adverse event monitoring, which is likely to drive stricter scrutiny of quality management systems and post-market data in future registration reviews. Companies should track how research outputs are translated into specific regulations or guidance documents so that product registration strategies can be adjusted in good time. For example, if the adverse event monitoring project recommends strengthening the responsibilities of the domestic agent, registration dossiers for imported devices may need to include more post-market surveillance materials.

2. Technical documentation and clinical evaluation

The emphasis on "serving regulatory decision-making with high-quality research results" suggests that future technical review may rely more heavily on regulatory decisions grounded in real-world evidence. Companies should optimize their clinical evaluation pathways in advance—particularly for devices requiring clinical trials—and consider incorporating real-world data to support safety and performance assessment. At the same time, outputs from the supervisory sampling and testing project may refine product testing standards, raising the performance verification requirements within technical documentation.

3. Quality systems and production supervision

Given the explicit focus on production supervision and supervisory sampling and testing, more detailed Good Manufacturing Practice (GMP) inspection points or unannounced inspection guidelines can be expected. Companies should proactively assess the compliance of their existing quality management systems; overseas manufacturers exporting to China in particular must ensure their quality systems meet China's current GMP requirements or standards that are about to be updated. In addition, supervisory sampling may extend to a broader range of imported product categories, so companies should establish internal mechanisms for responding to sampling and testing.

4. Post-market maintenance and compliance monitoring

Deeper work on adverse event monitoring means companies will need more robust post-market complaint handling and adverse event reporting systems. For products already registered in China, companies should review whether existing adverse event monitoring procedures meet potential new requirements and consider working with the domestic agent to build more efficient data collection channels. As further regulatory guidance is likely to emerge from this research, companies should assign dedicated staff to monitor regulatory developments and ensure timely updates to registration certificates, instructions for use and labels.

In summary, although this meeting reported interim results, it already makes clear that regulatory system research will stay closely aligned with the priorities of regulatory reform. Chinese medical device companies and overseas manufacturers should treat it as a forward-looking compliance signal and adjust the allocation of resources across registration, quality and post-market functions in advance of the anticipated regulatory upgrade. AIMEILI will continue to monitor the final research outputs and provide clients with accurate regulatory interpretation and optimization advice on registration strategy.

Frequently Asked Questions

Can the 3 July 2026 report meeting on medical device regulatory system research projects be used directly as a basis for an application?

No. A meeting report of this kind is not a regulatory requirement document and cannot serve as a filing basis. It is useful for preliminary understanding and project assessment only; formal applications must still be based on the latest requirements of the target country's regulatory authority, the applicable product classification conclusion and the company's actual documentation.

What should companies do first after seeing such an update?

Companies should first carry out a documentation gap assessment to confirm whether the update affects the registration pathway, technical documentation, labelling, quality management system or post-market maintenance obligations. Any impact identified should be translated into a concrete action list with owners and timelines.

Which documents should companies review as a priority?

Priority should be given to the intended use of the product, the classification rationale, ISO 13485 quality system evidence, risk management files, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents and existing registration certificates.

What are the common risks?

Common risks include unclear classification determinations, incomplete evidence chains in the documentation, labels and instructions for use that have not been localized, unclear responsibilities of the authorized representative, and inadequate post-market maintenance arrangements. When assessing requirements, companies should take a comprehensive view of the target country's regulatory pathway, the product's risk class, the basis of the technical file, label language, local authorized representative and post-market maintenance obligations.

Content Review and Scope of Application

• Content author: AIMEILI Regulatory Editorial Team
• Professional review: AIMEILI Medical Device International Registration Project Team
• Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
• Scope of application: This article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal opinions.